Middle East DNA Synthesis Market (2025 - 2033) Size, Share & Trends Analysis Report By Service Type (Oligonucleotide Synthesis, Gene Synthesis), By Application (Research Development, Diagnostics), By End Use, By Country, And Segment Forecasts

Middle East DNA Synthesis Market Trends

The Middle East DNA synthesis market size was estimated at USD 44.7 million in 2024 and is projected to reach USD 143.3 million by 2033, growing at a CAGR of 14.29% from 2025 to 2033. Increasing investments in biotechnology, developing research initiatives in genomics, and rising demand for synthetic biology applications across healthcare and industrial sectors in the region drive this growth.

Rising academic and clinical research activity is a significant driver of the DNA synthesis industry in the Middle East. Over the past decade, the region has witnessed substantial growth in research infrastructure, with governments and private stakeholders investing in universities, research centers, and teaching hospitals. Institutions across countries such as Saudi Arabia, the UAE, and Qatar increasingly prioritize genetic and molecular biology research, leading to heightened demand for synthetic DNA tools. These tools are essential for a wide range of applications, including gene editing, cloning, and the development of diagnostic assays. The increased availability of funding for R&D, along with collaborations with international research bodies, is further encouraging the adoption of DNA synthesis technologies in academic settings.

Cancer Clinical Trials Conducted In Saudi Arabia

Source: Clinical trial.gov.in, Secondary Research, Grand View Research

Moreover, the clinical research landscape in the Middle East is expanding, especially in precision medicine and translational genomics. Hospitals and medical research institutions are undertaking more clinical trials and biomarker discovery initiatives to understand disease mechanisms and develop targeted therapies. These efforts often rely heavily on synthetic oligonucleotides and gene constructs, further driving market demand. Moreover, national genomics initiatives such as the Qatar Genome Program and the Saudi Human Genome Program generate large volumes of genetic data, requiring synthetic DNA for validation, analysis, and downstream applications. Integrating genomics into healthcare and clinical decision-making is accelerating the use of DNA synthesis technologies across the region’s medical research ecosystem.

Increasing Focus on Precision Medicine and Genomics

The increasing focus on precision medicine and genomics is emerging as a key driver of the DNA synthesis industry in the Middle East. As countries in the region strive to modernize their healthcare systems, there is a growing emphasis on personalized treatment approaches that cater to the unique genetic profiles of individuals. For instance, in February 2025, a study in Nature Genetics highlighted the Greater Middle East's potential as a global genomics hub for rare diseases, despite data challenges and underutilized genetic diversity. Governments and healthcare institutions are investing in genome sequencing, molecular diagnostics, and genetic screening programs to support early diagnosis and targeted therapies. DNA synthesis plays a crucial role in these initiatives by enabling the design and production of synthetic genes, oligonucleotides, and other molecular tools used in genomic testing, biomarker validation, and developing precision drugs.

National genomics programs have accelerated this trend by driving large-scale demand for synthetic DNA. Initiatives such as the Saudi Human Genome Program and the Qatar Genome Program are focused on building comprehensive genomic databases to inform population-wide health strategies. These projects require vast amounts of synthetic DNA for sequencing validation, probe development, and functional genomic studies. Moreover, integrating genomic data into electronic health records and clinical workflows encourages hospitals and diagnostic labs to adopt DNA synthesis technologies for routine applications. As precision medicine becomes a central component of regional healthcare agendas, the need for scalable, reliable, and cost-effective DNA synthesis solutions is expected to grow significantly, making it a cornerstone of the market's expansion in the Middle East.

Market Concentration & Characteristics

The moderate degree of innovation in DNA synthesis technologies is a key driver of market growth in the Middle East, enabling faster, more accurate, and cost-effective production of synthetic DNA for a wide range of applications. Advances such as enzymatic synthesis, chip-based platforms, and automation have significantly improved the scalability and precision of DNA manufacturing, making it more accessible to research institutions, biotech startups, and clinical laboratories across the region. With strong government backing, national biotech strategies, and increasing collaboration with global technology providers, the Middle East rapidly embraces cutting-edge DNA synthesis solutions as a foundation for its expanding life sciences ecosystem.

M&A activity in the Middle East DNA synthesis industry is moderate but growing, driven by increasing interest in biotechnology and life sciences. Strategic partnerships and acquisitions are helping regional players access advanced technologies and expand capabilities. Government-backed investments and collaborations with global biotech firms are also boosting local innovation. As the market matures, M&A activity is expected to accelerate, reshaping the competitive landscape.

Regulations greatly impact the Middle East DNA synthesis industry, influencing how products are developed, approved, and used. As the region advances in biotechnology, governments establish clearer frameworks for genetic research, biosafety, and synthetic biology applications. While some countries still have evolving or fragmented regulatory systems, others like the UAE and Saudi Arabia are introducing national policies to govern genomics and biotechnology. These regulations aim to ensure ethical research, data protection, and biosafety, which can increase compliance costs, build trust, and attract investment. Strong regulatory clarity is expected to support sustainable market growth while balancing innovation with safety and ethical standards.

Service expansion drives growth in the Middle East DNA synthesis industry as providers broaden their offerings beyond basic oligonucleotide synthesis to include gene synthesis, plasmid construction, and CRISPR tools. With increased investment in local facilities and support centers, companies are improving accessibility and turnaround times, better serving the region’s growing research, biotech, and clinical sectors.

The Middle East DNA synthesis industry is expanding across countries like the UAE, Saudi Arabia, and Qatar, driven by rising demand for genomics and biotech innovation. Companies are setting up local facilities and partnerships to improve access and service delivery, making regional growth a key strategy for strengthening market presence.

Service Type Insights

The oligonucleotide synthesis segment accounted for the largest market revenue share in 2024, driven by its widespread use in research, diagnostics, and therapeutic development. The growing focus on personalized medicine, genetic screening programs, and infectious disease testing further supported the segment’s leading position. With ongoing advancements in synthesis technologies and increasing adoption of genomics-based applications, the oligonucleotide synthesis segment is expected to maintain its dominance over the forecast period.

The gene synthesis segment is anticipated to witness at the fastest CAGR over the forecast period. This growth is fueled by increasing demand for synthetic genes in applications such as vaccine development, therapeutic protein production, and synthetic biology research. As regional interest in biotechnology and precision medicine expands, gene synthesis becomes a critical tool for academic institutions, biotech startups, and pharmaceutical companies. Advancements in automation, reduced costs, and improved turnaround times further accelerate the adoption of gene synthesis services across the region.

Application Insights

The research and development segment led the market with the largest revenue share of 63.03% in 2024, owing to the growing investment in genomic research, molecular biology, and synthetic biology by academic institutions, government bodies, and biotech companies. Moreover, national genome programs and collaborations with global research organizations have further strengthened the role of R&D as the leading application segment in the region.

The therapeutics segment is projected to witness at the fastest CAGR over the forecast period. Increasing investments in biopharmaceutical R&D and growing regional efforts to localize drug manufacturing and reduce dependency on imports fuel demand for synthetic DNA in therapeutic development. For instance, in October 2023, major pharmaceutical firms expanded into the Middle East, especially Saudi Arabia, the UAE, and Qatar, driven by government investments, regulatory reforms, and Vision 2030 to localize pharma innovation. Moreover, advancements in synthetic biology and regulatory support for innovative therapies are accelerating the integration of DNA synthesis into next-generation treatment strategies across the region.

End Use Insights

The biopharmaceutical and diagnostics companies segment led the market with the largest revenue share of 49.62% in 2024. Biopharmaceutical companies increasingly rely on DNA synthesis to produce therapeutic proteins, conduct gene-based research, and develop personalized treatments. Simultaneously, diagnostic firms utilize synthetic oligonucleotides for assays, genetic screening, and infectious disease detection, particularly in response to rising regional healthcare needs and precision medicine initiatives.

The contract research organizations (CROs) segment is estimated to witness at the fastest CAGR throughout the forecast period. This growth is driven by the increasing outsourcing of research activities by pharmaceutical, biotech, and academic institutions aiming to reduce costs and accelerate development timelines. CROs offer specialized expertise in gene synthesis, molecular diagnostics, and clinical trial support, making them valuable partners in the region’s expanding biotech landscape. The rising number of clinical research projects and government support for life sciences innovation are expected to further boost demand for CRO services across the Middle East.

Country Insights

Kuwait Liquefied Natural Gas Market Trends

The DNA synthesis market in Kuwait is gradually growing, supported by increased investment in healthcare, genomics, and research infrastructure. The country is focusing on applications in diagnostics, genetic screening, and academic research, particularly for hereditary diseases and cancer. Collaborations with global biotech firms and the rising role of CROs are also contributing to market expansion. While still developing, Kuwait is emerging as a key player in the region's growing biotechnology landscape.

UAE Liquefied Natural Gas Market Trends

The UAE DNA synthesis market is a regional leader, driven by initiatives like the Emirati Genome Program and strong government investment in genomics and precision medicine. Growing research capacity, global biotech partnerships, and a focus on personalized healthcare fuel demand for synthetic DNA. The country’s advanced infrastructure and commitment to biotech innovation position it as a key player in the Middle East market.

Key Middle East DNA Synthesis Company Insights

The Middle East DNA synthesis industry is shaped by a mix of global biotechnology leaders and specialized players expanding their presence across the region through distribution networks, research collaborations, and technology partnerships. Companies such as Thermo Fisher Scientific, Twist Bioscience, GenScript, and Integrated DNA Technologies (IDT) are reinforcing their positions by offering robust product portfolios and customizable synthesis solutions that cater to the region's growing needs in genomics, diagnostics, and biopharmaceutical R&D.

Leading firms like GenScript, Twist Bioscience, and Eurofins Scientific are strengthening their market positions through strategic partnerships with academic institutions, local research centers, and healthcare providers in countries such as the UAE, Saudi Arabia, and Qatar. These companies are addressing increasing regional demand for synthetic genes, oligonucleotides, and CRISPR tools used in genetic research, vaccine development, and personalized medicine initiatives. Their advanced platforms and high-throughput capabilities make them key contributors to the regional synthetic biology ecosystem.

Organizations such as BIONEER Corporation, Eton Bioscience, LGC Biosearch Technologies, IBA Lifesciences, and Quintara Biosciences are actively participating by offering niche services, including custom oligo design, DNA/RNA purification kits, and molecular probes tailored to research and diagnostic applications. Through regional distributors and expanding service networks, these companies are enhancing accessibility to high-quality DNA synthesis technologies across both public and private sector labs.

The Middle East DNA synthesis industry is experiencing increasing momentum as key players capitalize on growing investment in genomics, healthcare innovation, and national biotechnology strategies. Intensifying competition is driven by a convergence of local demand, favorable government policies, and the push for self-sufficiency in life sciences. As the market evolves, companies that align their offerings with regional healthcare priorities—such as genetic disease screening, vaccine innovation, and precision therapeutics will be best positioned to capture long-term growth opportunities.

Recent Developments

• In March 2025, Thermo Fisher announced a USD 4.1 billion acquisition of Solventum's purification business to expand global biologics capacity. The deal, which will close by the end of 2025, strengthens Thermo Fisher's presence in emerging markets.

• In June 2022, Eurofins Scientific acquired a majority stake in Ajal for Laboratories, based in Riyadh, Saudi Arabia. The acquisition strengthened its food and pharmaceutical testing network across the Middle East.

• In October 2022, DNA Script expanded its distribution network into the Middle East by partnering with Gulf Scientific Corporation (covering Bahrain, Saudi Arabia, Kuwait, Oman, Qatar, and UAE) and Eisenberg Ltd. (Israel). This move enhanced access to its SYNTAX System, powered by Enzymatic DNA Synthesis (EDS), enabling same‑day in‑lab DNA oligo production and accelerating research workflows in genomics and synthetic biology.

Middle East DNA Synthesis Market Report Scope

Middle East DNA Synthesis Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the Middle East DNA synthesis market report based on the service type, application, end use, and country.

• Service Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Oligonucleotide Synthesis

    • By Type

      • Standard Oligonucleotide Synthesis

      • Custom Oligonucleotide Synthesis

    • By Length

      • Less than 50 nt

      • 51-100 nt

      • 101-150 nt

      • More than 150 nt

  • Gene Synthesis

    • By Type

      • Custom Gene Synthesis

      • Gene Library Synthesis

    • By Length

      • Less than 500 nt

      • 501-1000 nt

      • 1001-1500 nt

      • 1501-2000 nt

      • 2001-2500 nt

      • More than 2500 nt

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Research and Development

    • Oligonucleotide Synthesis

      • PCR

      • NGS

      • CRISPR

      • Cloning and Mutagenesis

      • Others

  • Gene Synthesis

    • Synthetic Biology

    • Vaccine Development

    • Genetic Engineering

    • Others

  • Diagnostics

  • Therapeutics

    • RNAi Therapies

    • Antisense Oligonucleotide-based Therapies

    • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Biopharmaceutical and Diagnostics Companies

  • Academic and Research Institutes

  • Contract Research Organizations

• Country Outlook (Revenue, USD Million, 2021 - 2033)

  • Saudi Arabia

  • UAE

  • Kuwait

  • Qatar

  • Oman

  • Rest of Middle East